SPOTLIGHT: Cancer cost hike tempered by generics

The average annual drug cost per cancer patient has reached new highs--$13,113 as of January 1, compared with $6,490 in 2001--but a new report shows that generics are being used more often, helping to slow the rate of that cost increase. Report

Suggested Articles

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.

Pfizer's Upjohn has reached a deal to exclusively supply generic Viagra to telehealth provider Roman as the company prepares to merge with Mylan.